Quantib® Prostate 2.0, our AI Powered Solution for Prostate MRI Reading and Reporting has received FDA clearance. Therefore, added to its CE mark, this upgrade is available in both Europe and the US.Read the full statement
The FDA cleared and CE marked zero-footprint artificial intelligence-based software provides a workflow for the detection of abnormalities on MRI prostate scans.
The FDA cleared and CE marked solution offers automated segmentation of brain structures and white matter hyperintensities.
At Quantib, we are focused on improving patient care by bringing artificial intelligence (AI) into clinical practice.
Started in 2012 as a spin-out from Erasmus MC, University Medical Center Rotterdam, Quantib now has AI partnerships with the three largest academic hospitals in the Netherlands and with hospitals and private providers internationally.
The tremendous value Quantib® ND adds is that the software delivers quantified information for our dementia patients and objective tracking of disease progression for our MS patients. Additionally, the software is remarkably user-friendly, enabling me to rapidly deliver even better funded, more detailed radiology reports to my clinicians.
Anna Sofie Knoepfli | Neuroradiologist at Swiss Medical, Clinique Du Genolier, Switzerland
Using Quantib® ND enables us to provide our clinicians with valuable objective information derived from our MRI scans. Comparing the patient's results to a non-biased reference population makes it easier for clinicians to give patients insights into their atrophy development.
Mario Muto | Director Diagnostic and Interventional Neuroradiology unit at Cardarelli Hospital, Naples
Quantib® ND clearly enables constructive multidisciplinary meetings by enabling efficient decision making. It provides a comprehensive overview of imaging results and compares outcomes to a normative database, therefore it enhances the quality of care we can deliver to our patients.
John van Swieten | Professor Genetics of Dementia at Erasmus MC, Rotterdam